Cancer immunotherapy now spans several very different technologies, and three of the most talked-about—CAR T-cell therapy, personalized mRNA vaccines, and bispecific antibodies (BiTEs)—work in fundamentally different ways. CAR T-cells are genetically engineered versions of a patient's own immune cells and are already FDA-approved for a range of blood cancers. Personalized mRNA vaccines train the immune system against a patient's unique tumor mutations and remain largely in clinical development. BiTEs are off-the-shelf drug molecules that physically link T-cells to cancer cells, with FDA-approved examples in leukemia and expanding research in other cancers. Here is how each one works, what it targets, and where it stands.
Introduction to Cutting-Edge Immunotherapies
Why do these three approaches get so much attention? Because each attacks cancer from a different angle. A scientific review of emerging immunotherapies describes the field as moving beyond broad immune stimulation toward precisely engineered interventions, including CAR cell therapy, which involves genetically engineering a patient's T cells to express specific receptors that can target and eliminate cancer cells.
That same review is candid about the field's limits. Several factors still constrain tumor-specific immune responses, including resistance mechanisms involving T-cell immune checkpoint pathways, intratumoral heterogeneity, inadequate production and function of tumor-specific CD8+ T cells, and a scarcity of suitable neoantigens with impaired processing and presentation. In other words, engineering the immune system is powerful but not yet universally effective.
We'll look at each approach in turn, then place them side by side. Note that this article compares three selected examples of cutting-edge immunotherapies, not an exhaustive list, and it is not medical advice.
CAR T-Cell Therapy: Engineering the Body's Defenders
How do you turn a patient's own blood cells into a cancer drug? CAR T-cell therapy starts with leukapheresis, a process in which white blood cells are collected from the patient's blood, as Moffitt Cancer Center's clinical perspectives explain. The T-cells among them are then genetically modified to carry a chimeric antigen receptor (CAR)—a synthetic receptor designed to recognize a specific marker on cancer cells.
Once reinfused, these engineered T-cells can find and kill cells displaying that marker. The FDA's December 2025 approval announcement for Breyanzi describes the mechanism plainly: the therapy "genetically engineers a patient's own T-cells to target and kill cancer cells."
The results in blood cancers have been striking. A review of approved CAR-T therapies notes that CAR T-cell therapy has established itself as a highly effective treatment for hematological malignancies, with six commercial CAR-T products FDA-approved for diseases such as B-ALL, LBCL, MCL, FL, MM, and CLL/SLL. Named products include Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), and Breyanzi (lisocabtagene maraleucel).
The FDA's clearance of the first CAR T-cell therapy, Kymriah, for some children and adults with advanced leukemia was described by the National Cancer Institute as a watershed event. Side effects reported in trials include neutropenia and anemia, and Moffitt reports having treated over 2,000 patients with CAR T therapy at its center alone.
Personalized mRNA Vaccines: Tailoring the Immune Response
What if the target isn't a shared cancer marker but a mutation found only in your tumor? That is the premise of personalized neoantigen vaccines. These are designed to stimulate the immune system specifically against tumor-specific neoantigens—mutated proteins unique to an individual's cancer.
The mechanism borrows directly from mRNA vaccine technology, similar to that used in COVID-19 vaccines. Recent advances have enabled the creation of personalized cancer vaccines using mRNA that encodes multiple neoantigens derived from a patient's tumor mutations. The patient's own cells produce those neoantigen instructions, and the immune system learns to recognize and attack cells bearing them.
Because the target is a tumor's unique genetic signature rather than a specific cancer type, the approach is in principle applicable across many cancer types, guided by genetic profiling of each patient's tumor. Dr. Nina Bhardwaj, an immunotherapy researcher profiled by the Cancer Research Institute, has highlighted recent results relating to neoantigen vaccines that target these patient-specific mutations, alongside new sequencing tools improving clinical capabilities.
Where does this approach stand? It remains a promising, emerging immunotherapy in active research and clinical trials rather than an established, widely approved treatment. That is the key distinction from CAR T-cells and BiTEs: the science is advancing quickly, but personalized mRNA cancer vaccines are not yet standard of care.
Bispecific Antibodies (BiTEs): Bridging Immune Cells and Cancer
Can a drug do what a cell does? Bispecific T-cell engagers, or BiTEs, are engineered antibodies that bind two different targets at once—one on a T-cell, typically CD3, and one on a cancer cell. By holding the two cells in close proximity, the antibody effectively forces the T-cell to attack the tumor.
The best-known example is blinatumomab (Blincyto). Moffitt's clinical team describes it as having shown significant efficacy in treating acute lymphoblastic leukemia by targeting CD19 on B cells and CD3 on T cells. Unlike CAR T-cell therapy, this is an administered drug rather than a manufactured cell product, which shapes its practical profile.
Expansion is underway. Moffitt reports active research and clinical trials aimed at extending bispecific antibodies to other cancers, including non-Hodgkin lymphoma—where they can target specific markers on B cells across subtypes—and multiple myeloma, where they can target B-cell maturation antigen (BCMA) on myeloma cells alongside CD3 on T-cells.
Industry analysis of FDA-approved BiTEs suggests that improved administration protocols and combination strategies could lead to additional approvals as next-generation therapies mature in clinical development. Current approvals, such as blinatumomab's in B-ALL, are indication-specific.
Immunotherapy Approaches at a Glance
The table below compares the three approaches across their mechanism, primary targets, and development status, so you can distinguish them at a glance.
| Therapy Type | Mechanism of Action | Primary Target Cancers | Development Status (Examples) |
|---|---|---|---|
| CAR T-cell therapy | Patient's T-cells are genetically engineered outside the body to express a chimeric antigen receptor that recognizes and destroys cancer cells. | Hematological malignancies: B-ALL, LBCL, MCL, FL, MM, CLL/SLL, and MZL, varying by product. | Six FDA-approved commercial products, including Kymriah, Yescarta, and Breyanzi; Breyanzi gained the first MZL indication in December 2025. |
| Personalized mRNA vaccines | mRNA encodes multiple neoantigens from a patient's tumor mutations, training the immune system to recognize and attack those targets. | Not a fixed cancer type: targets the unique, patient-specific mutations of an individual's tumor, implying broad potential applicability. | Largely in research and clinical trials; described as a promising, emerging approach with recent neoantigen vaccine results. |
| Bispecific antibodies (BiTEs) | Engineered antibodies bind CD3 on T-cells and an antigen on cancer cells simultaneously, bridging the two so the T-cell attacks. | Blinatumomab is FDA-approved for B-cell acute lymphoblastic leukemia; NHL and multiple myeloma under investigation. | Approved examples such as Blincyto in B-ALL; trials expanding use to additional cancers. |
Reading the table side by side reveals the core distinction. CAR T-cells are a living, engineered cell product made per patient. BiTEs are administered antibody drugs that recruit existing T-cells. Personalized mRNA vaccines aim to generate an immune response against mutations unique to each tumor. Two of the three have FDA-approved products; the third is still maturing through trials.
Understanding the Landscape of Cancer Immunotherapy
What should you take away when you see these terms in the news? Each approach represents a distinct strategy for overcoming the immune system's difficulty in recognizing cancer. CAR T-cells rewrite the T-cell's targeting instructions directly. BiTEs physically drag T-cells into contact with tumor cells. Personalized vaccines teach the immune system mutations it has never seen.
Keep the boundaries in mind. Approved CAR-T and BiTE products are indication-specific, concentrated in blood cancers, and clinical trial status plus FDA approvals change over time—this article reflects the state of development at the time of publication. Solid-tumor applications remain an active research frontier, and the resistance mechanisms described in the scientific review, from immune checkpoint pathways to scarce neoantigens, explain why.
Navigating Advanced Cancer Immunotherapies
Readers should recognize that cutting-edge immunotherapies offer distinct mechanisms for fighting cancer, with varying target cancers and stages of development, requiring careful consideration of individual cancer profiles. None of this is a recommendation for or against any treatment; treatment decisions belong with an oncology team informed by an individual diagnosis.
The reader can identify the specific mechanism and primary cancer targets when encountering news or discussions about CAR T-cell therapy, personalized mRNA vaccines, or Bispecific antibodies. A practical test: the next time a headline mentions one of these three, ask whether it describes engineered cells, a bridging antibody, or a mutation-targeting vaccine—and whether the news concerns an FDA approval or a trial result. That single distinction will tell you most of what you need to know.
Sources
- Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development - PMC
- Moffitt
- FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma In the US — U.S. Food and Drug Administration
- Approved CAR-T therapies have reproducible efficacy and safety in clinical practice - PMC
- FDA Approves Second CAR T-Cell Therapy — CANCER
- CRI Blogs — Cancer Research Institute
- How many FDA approved Bispecific T-cell Engager (BiTE) are there? — Synapse
